Profile data is unavailable for this security.
About the company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
- Revenue in USD (TTM)1.39m
- Net income in USD-258.54m
- Incorporated2008
- Employees290.00
- LocationCrinetics Pharmaceuticals Inc10222 Barnes Canyon Rd Bldg 2SAN DIEGO 92121-2711United StatesUSA
- Phone+1 (858) 450-6464
- Fax+1 (302) 636-5454
- Websitehttps://www.crinetics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 101.78m | -260.73m | 3.23bn | 226.00 | -- | 81.99 | -- | 31.71 | -4.37 | -4.37 | 1.71 | 2.94 | 0.2943 | 1.25 | 6.48 | 450,367.30 | -75.00 | -47.21 | -87.80 | -52.84 | 88.80 | -- | -254.88 | -681.38 | 6.31 | -- | 0.3765 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Amicus Therapeutics, Inc. | 455.66m | -119.54m | 3.35bn | 517.00 | -- | 25.25 | -- | 7.35 | -0.397 | -0.397 | 1.51 | 0.4471 | 0.6159 | 0.6948 | 6.12 | 881,344.30 | -16.16 | -30.65 | -20.75 | -36.55 | 89.88 | 88.94 | -26.23 | -86.10 | 2.26 | -0.6134 | 0.7459 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Alvotech SA | 308.73m | -618.38m | 3.35bn | 999.00 | -- | -- | -- | 10.86 | -2.65 | -2.65 | 1.28 | -2.27 | 0.312 | 1.80 | 3.66 | 309,038.00 | -62.49 | -- | -222.85 | -- | 48.79 | -- | -200.30 | -- | 0.1569 | -0.2323 | 2.04 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -118.49m | 3.42bn | 91.00 | -- | 4.28 | -- | -- | -2.25 | -2.25 | 0.00 | 13.65 | 0.00 | -- | -- | 0.00 | -25.44 | -- | -26.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -54.80m | 3.45bn | 50.00 | -- | 6.53 | -- | -- | -0.9043 | -0.9043 | 0.00 | 8.28 | 0.00 | -- | -- | 0.00 | -11.08 | -- | -11.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Dyne Therapeutics Inc | 0.00 | -257.60m | 3.67bn | 152.00 | -- | 4.73 | -- | -- | -3.58 | -3.58 | 0.00 | 7.74 | 0.00 | -- | -- | 0.00 | -47.82 | -52.81 | -50.15 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| TG Therapeutics Inc | 346.73m | 95.69m | 3.82bn | 300.00 | 41.08 | 21.49 | 39.82 | 11.01 | 0.6001 | 0.6001 | 2.29 | 1.15 | 1.11 | 0.4505 | 6.86 | 1,313,356.00 | 30.76 | -62.87 | 43.42 | -80.06 | 92.76 | -- | 27.60 | -405.03 | 2.83 | 8.21 | 0.3661 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Biohaven Ltd | 0.00 | -746.61m | 3.82bn | 239.00 | -- | 9.72 | -- | -- | -9.15 | -9.15 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -137.07 | -- | -176.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.39m | -258.54m | 4.25bn | 290.00 | -- | 5.07 | -- | 3,071.40 | -3.77 | -3.77 | 0.0201 | 10.47 | 0.0023 | -- | 0.4157 | 4,775.86 | -41.16 | -42.53 | -44.29 | -45.36 | -- | -- | -18,257.91 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Immunovant Inc | 0.00 | -272.55m | 4.28bn | 207.00 | -- | 7.85 | -- | -- | -1.92 | -1.92 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -57.93 | -- | -64.54 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Denali Therapeutics Inc | 1.27m | -419.65m | 4.43bn | 364.00 | -- | 3.19 | -- | 3,492.69 | -2.85 | -2.85 | 0.0085 | 9.69 | 0.0009 | -- | -- | 2,847.19 | -29.89 | -14.98 | -31.50 | -17.71 | -- | -- | -33,121.86 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Arcellx Inc | 144.75m | -53.89m | 4.66bn | 130.00 | -- | 9.53 | -- | 32.17 | -1.05 | -1.05 | 2.84 | 9.08 | 0.2132 | -- | -- | 1,113,423.00 | -7.94 | -38.82 | -9.68 | -45.41 | -- | -- | -37.23 | -339.38 | -- | -- | 0.038 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Alkermes Plc | 1.51bn | 457.54m | 4.70bn | 2.10k | 10.68 | 3.69 | 9.23 | 3.12 | 2.67 | 1.69 | 8.78 | 7.74 | 0.6864 | 1.31 | 4.28 | 718,055.30 | 20.83 | 1.34 | 26.98 | 1.74 | 83.31 | 83.32 | 30.34 | 2.12 | 2.61 | -- | 0.184 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Madrigal Pharmaceuticals Inc | 14.64m | -510.45m | 5.07bn | 376.00 | -- | 5.91 | -- | 346.34 | -25.50 | -25.50 | 0.7351 | 39.50 | 0.0209 | -- | -- | 38,930.85 | -72.80 | -62.09 | -86.71 | -74.81 | 95.66 | -- | -3,487.13 | -- | 8.67 | -- | 0.1198 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
Data as of Sep 20 2024. Currency figures normalised to Crinetics Pharmaceuticals Inc's reporting currency: US Dollar USD
50.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Driehaus Capital Management LLCas of 30 Jun 2024 | 6.11m | 7.64% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 5.54m | 6.92% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 4.34m | 5.43% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 4.32m | 5.40% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.31m | 5.38% |
| EcoR1 Capital, LLCas of 30 Jun 2024 | 4.16m | 5.19% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 3.51m | 4.39% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.81m | 3.52% |
| Point72 Asset Management LPas of 30 Jun 2024 | 2.78m | 3.48% |
| Jennison Associates LLCas of 30 Jun 2024 | 2.78m | 3.47% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
